BlueChip Wealth Advisors LLC Makes New $535,000 Investment in AbbVie Inc. $ABBV

BlueChip Wealth Advisors LLC purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,311 shares of the company’s stock, valued at approximately $535,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie during the second quarter valued at $26,000. Spurstone Advisory Services LLC acquired a new stake in AbbVie in the second quarter worth about $28,000. Financial Gravity Companies Inc. acquired a new stake in AbbVie in the second quarter worth about $36,000. Delos Wealth Advisors LLC bought a new stake in AbbVie during the 2nd quarter worth about $39,000. Finally, Access Investment Management LLC acquired a new position in AbbVie during the 2nd quarter valued at about $44,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on ABBV. Berenberg Bank set a $275.00 target price on shares of AbbVie in a research note on Tuesday, January 20th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. JPMorgan Chase & Co. lifted their target price on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. BMO Capital Markets restated an “outperform” rating and set a $258.00 target price on shares of AbbVie in a research report on Thursday, January 15th. Finally, DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a research report on Tuesday, November 4th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $251.00.

AbbVie Stock Down 0.4%

NYSE:ABBV opened at $222.32 on Wednesday. The stock’s 50 day moving average price is $223.67 and its two-hundred day moving average price is $220.29. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The firm has a market capitalization of $392.93 billion, a price-to-earnings ratio of 94.20, a P/E/G ratio of 0.78 and a beta of 0.35.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the previous year, the company posted $2.16 earnings per share. The business’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.